Skip to content

Spyre Therapeutics

US · SYRE #1646 by market cap Listed 1970
93.47 -4.16 -4.26%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 96.05 -1.62%
After-hours 93.47 0.00%
109.0069.1693.472026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on SYRE?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +142.5% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 12.6% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days B → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall B+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability F

How much profit the business keeps from each dollar of sales and capital.

Operating margin -14,510.6% Better than 1%
Net margin -38,238.1% Better than 0%
Return on equity -33.7% Better than 12%
Return on invested capital -39.1% Better than 8%
Momentum A-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -12.2% Better than 45%
6-month return 26.2% Better than 87%
12-month return (ex latest month) 272.3% Better than 99%
Distance below 52-week high 15.5% Better than 70%
Financial Health A+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 13.3x Better than 96%
Debt to assets 6.5% Better than 76%
Analyst View B+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 32.0% Better than 51%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -10.13%
1M +2.26%
3M -13.29%
6M +29.96%
YTD +185.32%
1Y +298.25%
3Y +790.19%
5Y -44.03%

Key statistics

Price & volume

Prev close
97.63
Open
95.93
Day range
93.22 - 99.56
Avg price
94.65
Volume
805.36K
Turnover
76.23M
Amplitude
6.49%
52-week range
24.58 - 110.64

Valuation

P/E
-47.21
P/E (TTM)
-33.62
P/B
9.81
EPS
-1.98
Net profit
-188.04M
Net assets
905.15M

Share structure

Market cap
8.88B
Float cap
8.65B
Shares out
94.97M
Float shares
92.51M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 80% of range
24.58 110.64

15.5% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-18.44M net over the window

Short interest

Shares short
11.62M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Spyre Therapeutics (SYRE)?

Spyre Therapeutics last traded at 93.47. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Spyre Therapeutics's market cap?

About 8.88B.

What is the P/E ratio of Spyre Therapeutics?

The trailing twelve-month P/E is -33.62. The Valuation tab shows it against the stock's own five-year range.

Does Spyre Therapeutics pay a dividend?

Spyre Therapeutics does not currently pay a regular dividend.

Is Spyre Therapeutics a buy according to analysts?

The consensus of 13 analysts is a Buy rating, with an average 12-month price target of 123.38, which implies 32.0% upside from the current price. This is not investment advice.

What is Spyre Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Spyre Therapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Spyre Therapeutics discussion 0 comments

Add a comment